> ## Content Index > Fetch the complete content index at: https://brief.sharpertrades.com/llms.txt > Use this file to discover other available public pages before exploring further. # Johnson & Johnson's MedTech Slowdown Weighs on Shares Despite Strong Drug Sales and Higher Guidance - URL: https://brief.sharpertrades.com/johnson-johnsons-medtech-slowdown-weighs-on-shares-despite-strong-drug-sales-and-higher-guidance/ - Published: 2026-10-13T16:52:00.000Z - Updated: 2026-10-13T21:02:03.000Z - Description: Johnson & Johnson shares fell nearly 6% despite stronger-than-expected earnings and raised guidance. Slowing MedTech growth, a $5.5 billion talc litigation charge and plans to separate its orthopedics business drew investor attention. - Author: Luca Moschini - Tags: Earnings, Business Trends, Sector ### Strong Pharmaceutical Growth Fails to Offset MedTech Concerns Johnson & Johnson (JNJ) shares fell nearly 6% on Tuesday, October 13, as investors focused on slowing medical device sales and litigation expenses despite better-than-expected third-quarter earnings and another increase to the company's full-year outlook. The healthcare giant reported revenue of $25.4 billion, up 5.9% from a year earlier, while adjusted earnings of $2.59 per share exceeded Wall Street expectations. However, disappointing growth in its MedTech division, a substantial talc-related charge and a modest guidance increase overshadowed the strength of its pharmaceutical business. --- ### Key Points - MedTech weakness drives the sell-off: Revenue growth in Johnson & Johnson's medical technology division slowed to 2.5%, reflecting international spending constraints, competitive pressure and weakness in certain cardiovascular products. - Pharmaceutical sales remain strong: Innovative Medicine revenue increased approximately 8% on an operational basis, supported by strong demand for Tremfya, Caplyta and other newer treatments. - Litigation and restructuring remain in focus: A $5.52 billion pretax charge tied primarily to talc litigation sharply reduced reported earnings, while management indicated that a spinoff is its preferred approach for separating the orthopedics business. --- ## Why Did Johnson & Johnson Stock Fall Despite Beating Earnings Expectations? Johnson & Johnson delivered a solid third-quarter performance at the consolidated level, but the results revealed a widening gap between its pharmaceutical and medical technology businesses. Adjusted earnings of $2.59 per share exceeded the approximately $2.52–$2.53 consensus estimate. Revenue rose 5.9% to $25.4 billion, broadly meeting expectations. However, adjusted earnings declined 7.5% from a year earlier, and reported earnings under generally accepted accounting principles fell to just $0.09 per share. The sharp decline in reported profitability reflected a $5.52 billion pretax litigation charge, primarily associated with the company's proposed $5.5 billion settlement of remaining ovarian talc claims. The proposed resolution requires participation from 95% of claimants. Under the contemplated agreement, Johnson & Johnson would pay no more than $3 billion in 2027. The company treated the charge as a special item excluded from adjusted earnings, but its effect on reported profitability was substantial. ### Higher Guidance Offers Limited Relief Johnson & Johnson also raised its full-year outlook, continuing a pattern of upward revisions throughout 2026. Management now expects adjusted earnings of $11.05 to $11.15 per share, compared with its previous forecast of $10.96 to $11.11. The company also lifted the lower end of its sales guidance, targeting approximately $101.2 billion at the midpoint. Although the revisions reflect management's confidence in overall business performance, the increase was relatively modest. The revised adjusted earnings range also remained below the FactSet consensus of $11.19 per share. Investors appeared more concerned about the performance of MedTech and the company's earnings outlook than the headline earnings beat. Shares declined approximately 6%, putting the stock on course for its steepest one-day percentage decline since April 2025. ## MedTech Growth Slows as International Pressures Mount Johnson & Johnson's MedTech division was the central disappointment in the quarterly report. Revenue increased just 2.5% to $8.64 billion, missing Wall Street expectations of approximately $8.74 billion. The slowdown was particularly notable compared with earlier quarters. MedTech growth had reached 7.7% in the first quarter before moderating to 4.6% in the second. Third-quarter sales also declined sequentially from $8.93 billion. The weakness extended across the division, with all four major MedTech segments falling short of expectations. U.S. operational sales increased 4.8%, while international growth was essentially flat at 0.1%. ### Middle East Disruptions and Cardiovascular Weakness Chief Financial Officer Joe Wolk attributed part of the international slowdown to geopolitical and economic pressures. In the Middle East, ongoing conflict has prompted some countries to redirect spending toward defense rather than healthcare. European budget constraints and China's volume-based procurement policies have created additional challenges. The latter puts pressure on medical device pricing through centralized purchasing programs. Johnson & Johnson also faced competitive pressure in electrophysiology and lower patient volumes for its Impella heart pumps. Impella, acquired through the company's purchase of Abiomed in 2022, has experienced weaker demand following a U.K. study that raised questions about its use in certain high-risk, nonemergency procedures. Wolk acknowledged the challenge and said the company expects to release results from a larger, 252-patient study next year. Despite the revenue slowdown, MedTech's adjusted pretax margin improved to 22.9% from 21.0%, indicating that weaker sales growth did not translate into a corresponding deterioration in segment profitability. ### Orthopedics Spinoff Could Reshape the Business Management is also advancing plans to separate its orthopedics business, DePuy Synthes. Wolk indicated that a spinoff is currently the preferred option, rather than selling the business to another company. The decision reflects management's view that depressed medical technology valuations could make an outright sale less attractive. Johnson & Johnson is targeting a separation around mid-2027. Orthopedics generated more than $9.2 billion in global revenue last year and remains one of MedTech's largest businesses. Separating the unit would allow the remaining MedTech organization to concentrate more heavily on cardiovascular devices and robotic surgery. The company is already placing its Ottava robotic surgery system with customers following regulatory approval in July. Ottava will compete with established robotic surgery platforms, including those developed by Intuitive Surgical (ISRG). However, a spinoff would also remove the orthopedics business's earnings contribution and introduce separation expenses, making the financial structure of the transaction important to its eventual impact. ## Pharmaceutical Growth Strengthens as New Drugs Gain Momentum While MedTech disappointed, Johnson & Johnson's Innovative Medicine business delivered strong growth. Pharmaceutical revenue increased approximately 7.7% to $16.76 billion, representing roughly two-thirds of total company sales. The division benefited from growing demand for newer treatments across immunology, oncology and neuroscience. Tremfya, used to treat psoriasis and inflammatory conditions, remained a standout performer, with sales increasing approximately 68%. Wolk said the company believes Tremfya could eventually become a product generating more than $10 billion in annual revenue, citing opportunities in inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The treatment's growth is particularly important as Johnson & Johnson manages declining sales of Stelara, an older immunology product facing biosimilar competition. Stelara sales fell approximately 54% during the quarter, but newer medicines helped offset much of that pressure. ### Icotyde Expands the Psoriasis Treatment Market Another important development is the early adoption of Icotyde, Johnson & Johnson's once-daily oral treatment for plaque psoriasis. The drug has generated approximately 20,000 prescriptions since its introduction earlier this year, supported by a prescribing base of roughly 9,000 healthcare professionals. Management has not yet disclosed separate revenue figures for Icotyde, partly because free medication provided during the launch has reduced recognized sales. Wolk indicated that revenue could be approximately twice its current level without those free supplies. Importantly, Icotyde's adoption has not reduced demand for Tremfya. According to management, the oral treatment is reaching patients who may be reluctant to use injectable biologic therapies, potentially expanding the population receiving treatment. Other pharmaceutical products also contributed to growth. Caplyta sales increased approximately 66%, supported by expanded use in depression treatment, while Spravato grew 36%. Johnson & Johnson's oncology portfolio remained strong, with operational sales advancing 16.7%. Multiple myeloma treatments, including Darzalex and Tecvayli, contributed to the division's performance. The pharmaceutical results demonstrate the company's ability to generate growth from newer products even as older treatments face competitive pressure. --- ## What It Means for Investors Johnson & Johnson's third-quarter results highlight a company with two businesses moving at different speeds. Innovative Medicine continues to benefit from strong demand for newer treatments, helping offset declining revenue from older products such as Stelara. MedTech, however, faces a more complicated operating environment. International healthcare spending constraints, pricing pressure and product-specific challenges have slowed growth despite improving segment margins. The proposed orthopedics spinoff represents an important strategic development, but its financial implications remain dependent on the eventual separation structure. Investors are also assessing the company's ability to translate pharmaceutical sales growth into stronger earnings. Although Johnson & Johnson raised its full-year guidance, the modest increase did not fully address concerns about MedTech performance and the earnings impact of ongoing investments. The talc litigation charge adds another layer of complexity. While the expense was excluded from adjusted results, the proposed settlement remains subject to claimant participation requirements. Looking ahead, several developments will help clarify the company's outlook: whether MedTech sales growth improves, how newer pharmaceutical products continue to perform, and what financial details emerge around the planned orthopedics separation. ## Conclusion Johnson & Johnson's third-quarter earnings revealed strong pharmaceutical momentum alongside slowing medical technology growth. The company exceeded earnings expectations and raised its full-year outlook, supported by growing demand for treatments including Tremfya, Caplyta and Icotyde. However, weaker MedTech sales, international spending pressures and a substantial talc litigation charge overshadowed those results, contributing to a sharp decline in the company's shares. Management's preference for spinning off the orthopedics business signals an effort to reshape the medical technology portfolio and concentrate on higher-growth opportunities. The central question is whether Johnson & Johnson can restore momentum in MedTech while sustaining the pharmaceutical growth that currently supports much of its business. ## FAQs ### Why did Johnson & Johnson stock fall after reporting better-than-expected earnings? Johnson & Johnson shares declined because investors focused on slowing MedTech sales, a substantial talc litigation charge and a relatively modest increase in full-year guidance. Strong pharmaceutical results were not enough to offset those concerns. ### How did Johnson & Johnson's MedTech division perform in the third quarter? MedTech revenue increased 2.5% to $8.64 billion, below Wall Street expectations. Growth was constrained by international healthcare spending pressures, competitive challenges and weaker demand for certain cardiovascular products. ### What caused Johnson & Johnson's reported earnings to fall so sharply? Reported earnings fell to $0.09 per share, largely because of a $5.52 billion pretax litigation charge associated primarily with the company's proposed settlement of remaining ovarian talc claims. ### Which pharmaceutical products drove Johnson & Johnson's growth? Tremfya, Caplyta, Spravato and several oncology treatments contributed to growth. The company also reported encouraging early prescription activity for Icotyde, its oral psoriasis treatment. ### Is Johnson & Johnson planning to spin off its orthopedics business? Management indicated that a spinoff is its preferred approach for separating DePuy Synthes, with the broader orthopedics separation targeted for mid-2027\. The final financial structure has not yet been established. *This article was created with AI assistance and reviewed by an editor. For details, please refer to our* [*Terms of Use*](https://sharpertrades.com/p/terms?ref=brief.sharpertrades.com)*.* --- ### Go Beyond the Market Brief with Market Edge Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass.[*Try Market Edge for $19 your first month →*](https://sharpertrades.com/p/market-edge?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) ### Explore Research with Stock Investor [*Stock Investor*](https://sharpertrades.com/p/stock-investor/?ref=brief.sharpertrades.com) is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions. ### Explore Active Trading & Income Strategies [*Block Orders*](https://sharpertrades.com/p/block-orders?coupon%5Fcode=MB1&ref=brief.sharpertrades.com) tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities. For options-focused traders, [*Essential Option Income*](https://sharpertrades.com/p/option-alert-trading-signal?coupon%5Fcode=MB1&ref=brief.sharpertrades.com) provides a structured approach to options income strategies, while [*Pro Option Trader*](https://sharpertrades.com/p/pro-option-alert-trading-signal?coupon%5Fcode=MB19&ref=brief.sharpertrades.com) offers a broader range of options strategies and trade opportunities. ### Think More Clearly with SteadyCapital [SteadyCapital](https://studio.com/luca/steadycapital?c=fVDR9OI2&ref=brief.sharpertrades.com) is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act. ### Risk Disclosure All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full [Risk Disclosure](https://sharpertrades.com/p/risk-disclaimer?ref=brief.sharpertrades.com) for additional information.